Eisai Vietnam opens new office and enters strategic partnership

May 14, 2022 | 13:08
On May 12, Eisai Vietnam Co., Ltd. announced the opening of its new office and signed a four-year cooperation relationship with the Vietnam Association of Neurology, marking its strong 30-year presence in the Vietnamese market.
Eisai Vietnam opens new office and enters strategic partnership
The opening of Eisai's new office in District 3, Ho Chi Minh City

The company’s new office is located in Saigon Giai Phong Tower, 432-438 Nguyen Thi Minh Khai street in District 3, Ho Chi Minh City.

Eisai Vietnam also signed an MoU with the Vietnam Neurological Association to increase access to diagnosis and improve the quality of treatment for the Alzheimer's community up to 2025.

Eisai Vietnam is a wholly-owned subsidiary of Eisai Co., Ltd. – a leading global research and development-based pharmaceutical company headquartered in Japan. Founded in 1941, Eisai Group currently has 46 companies and subsidiaries and more than 10,000 employees worldwide.

Eisai's corporate philosophy is to think about patients and their families first and to increase the benefits that health care provides to address significant unmet medical needs.

Eisai's corporate philosophy is to think about patients and their families first and to increase the benefits that health care provides to address significant unmet medical needs.

Eisai calls this the Human Health Care philosophy. As part of this, Eisai is working to enhance its corporate value in a sustainable way by strengthening various initiatives in areas such as environmental, social, and governance standards.

Eisai started business in Vietnam through a local agency in the 1990s. The company opened a representative office in Ho Chi Minh City which mainly markets the proton-pump inhibitor Pariet, the muscle relaxant Myonal, and the peripheral neuropathy treatment Methycobal.

In addition, regarding its global products in Vietnam, Eisai recently launched its antiepileptic drug Fycompa in October 2019, and obtained marketing approval for the anti-cancer agent Lenvima in June 2020 and Halaven in December last year.

Appreciating the potential of the Vietnamese market, Yuki Inoue, general director of Eisai Vietnam said, “The number of people suffering from non-communicable diseases has been increasing. In response to this health care demand, Eisai Vietnam has decided to open an official office in Vietnam in order to improve pharmaceutical distribution to the market with innovative drugs and contribute to improving the lives of patients and their families.”

Eisai Vietnam opens new office and enters strategic partnership
The MoU signing ceremony between Eisai Vietnam and the Vietnam Neurological Association

Together with the association, Eisai Vietnam will carry out public activities to educate and raise awareness of Alzheimer's disease, as well as build capacity for diagnosis and medical knowledge about treatments.

After oncology, neurology is one of the two focus areas of the Eisai Group with its 35 years of research and the development of new drugs for dementia.

In this field, Eisai has made a major contribution to supporting the prevention and treatment of next-generation dementia. Globally, Eisai is also a leader in signing partnerships with companies in the insurance, food, and financial sectors to improve the quality of life for dementia patients.

Thanks to its social efforts and initiatives, the company was honoured by Corporate Knights in the Top 100 Most Global Sustainable Corporations in 2022.

By Anh Duc

What the stars mean:

★ Poor ★ ★ Promising ★★★ Good ★★★★ Very good ★★★★★ Exceptional